{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T03:06:25Z","timestamp":1788318385184,"version":"build-2803163510"},"reference-count":18,"publisher":"Georg Thieme Verlag KG","issue":"04","license":[{"start":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T00:00:00Z","timestamp":1659916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TH Open"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Background\u2003Nephrotic syndrome (NS) is associated with an increased risk of thromboembolic events (TEs), due to hemostatic derangements. The use of direct oral anticoagulants (DOACs) in the prevention of TE has not been studied intensively in patients suffering from NS.<\/jats:p>\n                  <jats:p>Methods\u2003The method included retrospective analysis of consecutive incident patients with NS due to glomerular disease, receiving apixaban for thromboprophylaxis. It is an uncontrolled, single-center study.<\/jats:p>\n                  <jats:p>Results\u2003We identified 27 patients treated with apixaban for the prevention of TEs, in the context of NS. During follow-up, apixaban minimal blood concentration (trough level; Cmin) and maximum blood concentration (Cmax) levels were measured. The mean duration of the anticoagulant treatment was 153 days (\u00b1132). Patients were followed for a mean of 14.7 months (\u00b18.4) since the introduction of apixaban. Three patients had a TE at the time of NS diagnosis. Two patients had pulmonary embolism (PE) and one patient presented a stroke in a lupus membranous nephropathy context. One patient developed PE approximately 2 months after the introduction of apixaban treatment. No minor or major bleeding events were noticed.<\/jats:p>\n                  <jats:p>Conclusion\u2003The present study shows that patients, suffering from severe NS under anticoagulant therapy with apixaban had a reduced risk of venous and arterial TEs compared with patients previously described in the literature, without increased risk of bleeding.<\/jats:p>","DOI":"10.1055\/a-1920-6224","type":"journal-article","created":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T18:48:46Z","timestamp":1659984526000},"page":"e299-e303","source":"Crossref","is-referenced-by-count":17,"title":["Apixaban Prophylactic Anticoagulation in Patients with Nephrotic Syndrome"],"prefix":"10.1055","volume":"06","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9018-9278","authenticated-orcid":false,"given":"Tess","family":"Van Meerhaeghe","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Dialysis, H\u00f4pital Erasme ULB, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Cez","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Dialysis, Assistance Publique H\u00f4pitaux de Paris, H\u00f4pital Tenon, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Dahan","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Dialysis, Assistance Publique H\u00f4pitaux de Paris, H\u00f4pital Tenon, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Esteve","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Dialysis, Assistance Publique H\u00f4pitaux de Paris, H\u00f4pital Tenon, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismail","family":"Elalamy","sequence":"additional","affiliation":[{"name":"Hematology and Thrombosis Center, H\u00f4pital Tenon, H\u00f4pitaux Universitaires de l'Est Parisien, Assistance Publique H\u00f4pitaux de Paris, Facult\u00e9 de M\u00e9decine, Sorbonne Universit\u00e9, Paris, France"},{"name":"Research Group Cancer, Haemostasis and Angiogenesis, INSERM U938, Centre de Recherche Saint-Antoine, Institut Universitaire de Canc\u00e9rologie, Faculty of Medicine, Sorbonne University, Paris, France"},{"name":"Sorbonne Universit\u00e9, INSERM UMRS1155, H\u00f4pital Tenon, Paris, France"},{"name":"Department of Obstetrics and Gynaecology, The First I.M. Sechenov Moscow State Medical University, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Jacques","family":"Boffa","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Dialysis, Assistance Publique H\u00f4pitaux de Paris, H\u00f4pital Tenon, Paris, France"},{"name":"Sorbonne Universit\u00e9, INSERM UMRS1155, H\u00f4pital Tenon, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonore","family":"Ponlot","sequence":"additional","affiliation":[{"name":"Departement of Nephrology and Dialysis, Grand H\u00f4pital de Charleroi GHDC, Charleroi, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2022,10,7]]},"reference":[{"issue":"03","key":"ref1","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2215\/CJN.10131011","article-title":"Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease","volume":"7","author":"B A Kerlin","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"02","key":"ref2","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/ki.2011.312","article-title":"Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis","volume":"81","author":"S J Barbour","year":"2012","journal-title":"Kidney Int"},{"issue":"01","key":"ref3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/ndt\/gfw227","article-title":"Association of serum albumin level and venous thromboembolic events in a large cohort of patients with nephrotic syndrome","volume":"32","author":"G Gyamlani","year":"2017","journal-title":"Nephrol Dial Transplant"},{"issue":"04","key":"ref4","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s11255-013-0574-0","article-title":"Risk factors for predicting venous thromboembolism in patients with nephrotic syndrome: focus on haemostasis-related parameters","volume":"46","author":"G Ismail","year":"2014","journal-title":"Int Urol Nephrol"},{"issue":"02","key":"ref5","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1161\/CIRCULATIONAHA.107.716951","article-title":"High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study","volume":"117","author":"B K Mahmoodi","year":"2008","journal-title":"Circulation"},{"issue":"01","key":"ref6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12882-019-1336-8","article-title":"Prophylactic anticoagulation in nephrotic syndrome prevents thromboembolic complications","volume":"20","author":"S Kelddal","year":"2019","journal-title":"BMC Nephrol"},{"issue":"03","key":"ref7","doi-asserted-by":"crossref","first-page":"478","DOI":"10.2215\/CJN.07190713","article-title":"Retrospective analysis of a novel regimen for the prevention of venous thromboembolism in nephrotic syndrome","volume":"9","author":"N Medjeral-Thomas","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"issue":"01","key":"ref8","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000188355","article-title":"Prevention of thrombotic complications of the nephrotic syndrome by the low-molecular-weight heparin enoxaparin","volume":"69","author":"G Rostoker","year":"1995","journal-title":"Nephron J"},{"issue":"04","key":"ref9","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ekir.2018.02.010","article-title":"Direct-acting oral anticoagulants as prophylaxis against thromboembolism in the nephrotic syndrome","volume":"3","author":"D J Sexton","year":"2018","journal-title":"Kidney Int Rep"},{"key":"ref10","first-page":"64","article-title":"Warfarin vs. new oral anticoagulant in primary adult nephrotic syndrome associated venous thromboembolism","volume":"22","author":"T HC Han","year":"2017","journal-title":"Nephrology (Carlton)"},{"issue":"01","key":"ref12","first-page":"739","article-title":"Rivaroxaban for the treatment of venous thromboembolism in patients with nephrotic syndrome and low AT-III: a pilot study","volume":"15","author":"L Zhang","year":"2018","journal-title":"Exp Ther Med"},{"issue":"12","key":"ref13","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1177\/1060028014549349","article-title":"Use of rivaroxaban in a patient with history of nephrotic syndrome and hypercoagulability","volume":"48","author":"L H Dupree","year":"2014","journal-title":"Ann Pharmacother"},{"issue":"04","key":"ref14","doi-asserted-by":"crossref","first-page":"212","DOI":"10.5662\/wjm.v5.i4.212","article-title":"Monitoring anticoagulant therapy with new oral agents","volume":"5","author":"A Ramos-Esquivel","year":"2015","journal-title":"World J Methodol"},{"issue":"10","key":"ref15","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s40262-019-00775-z","article-title":"Apixaban: a clinical pharmacokinetic and pharmacodynamic review","volume":"58","author":"W Byon","year":"2019","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"ref16","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"C B Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"09","key":"ref17","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"G Agnelli","year":"2013","journal-title":"N Engl J Med"},{"issue":"08","key":"ref18","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"G Agnelli","year":"2013","journal-title":"N Engl J Med"},{"issue":"01","key":"ref19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2215\/CJN.04250511","article-title":"Venous thromboembolism in patients with membranous nephropathy","volume":"7","author":"S Lionaki","year":"2012","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["TH Open"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1920-6224.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T18:44:00Z","timestamp":1665168240000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1920-6224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,8]]},"references-count":18,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2022,10,7]]},"published-print":{"date-parts":[[2022,10]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1920-6224","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2512-9465"],"issn-type":[{"value":"2512-9465","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,8,8]]},"published":{"date-parts":[[2022,8,8]]}}}